Godavari Drugs Limited (BOM:530317)
India
· Delayed Price · Currency is INR 82.89
+2.60 (3.24%)
At close: Mar 10, 2026
Godavari Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 981.48 | 1,134 | 1,567 | 1,596 | 1,611 | 1,227 | Upgrade
|
| Other Revenue | 5.47 | 7.55 | 5.1 | - | 1.55 | 1.43 | Upgrade
|
| Revenue | 986.94 | 1,141 | 1,572 | 1,596 | 1,613 | 1,228 | Upgrade
|
| Revenue Growth (YoY) | -22.20% | -27.42% | -1.50% | -1.01% | 31.31% | 28.26% | Upgrade
|
| Cost of Revenue | 709.32 | 828.66 | 1,222 | 1,295 | 1,328 | 978.97 | Upgrade
|
| Gross Profit | 277.63 | 312.39 | 350.35 | 301.26 | 284.42 | 249.17 | Upgrade
|
| Selling, General & Admin | 59.54 | 52.05 | 52.56 | 49.59 | 50.65 | 40.43 | Upgrade
|
| Other Operating Expenses | 104.68 | 131.45 | 158.07 | 133.08 | 116.86 | 108.91 | Upgrade
|
| Operating Expenses | 189.13 | 207.97 | 230.57 | 202.11 | 184.48 | 161.56 | Upgrade
|
| Operating Income | 88.5 | 104.42 | 119.78 | 99.15 | 99.94 | 87.6 | Upgrade
|
| Interest Expense | -41.31 | -47.32 | -49.15 | -39.27 | -28.49 | -31.89 | Upgrade
|
| Interest & Investment Income | 1.06 | 1.06 | 1.07 | 1.29 | 1.1 | 0.8 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.07 | -3.07 | -1.58 | -18.03 | -2.34 | 1.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.82 | 0.82 | - | 3.93 | - | -1.32 | Upgrade
|
| EBT Excluding Unusual Items | 45.99 | 55.91 | 70.12 | 47.05 | 70.21 | 57.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.35 | 0.35 | - | - | - | - | Upgrade
|
| Other Unusual Items | 2.51 | - | -0.9 | 2.3 | - | - | Upgrade
|
| Pretax Income | 48.85 | 56.25 | 69.22 | 49.35 | 70.21 | 57.06 | Upgrade
|
| Income Tax Expense | 11.94 | 12.45 | 13.73 | 11.49 | 17.75 | 15.78 | Upgrade
|
| Net Income | 36.92 | 43.8 | 55.49 | 37.86 | 52.45 | 41.28 | Upgrade
|
| Net Income to Common | 36.92 | 43.8 | 55.49 | 37.86 | 52.45 | 41.28 | Upgrade
|
| Net Income Growth | -39.96% | -21.07% | 46.57% | -27.82% | 27.06% | 106.33% | Upgrade
|
| Shares Outstanding (Basic) | 8 | 8 | 8 | 8 | 8 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 8 | 8 | 8 | 8 | 8 | Upgrade
|
| Shares Change (YoY) | -0.06% | -0.04% | 0.03% | 0.01% | -0.10% | 0.15% | Upgrade
|
| EPS (Basic) | 4.91 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | Upgrade
|
| EPS (Diluted) | 4.91 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | Upgrade
|
| EPS Growth | -39.93% | -21.03% | 46.52% | -27.83% | 27.19% | 106.01% | Upgrade
|
| Free Cash Flow | - | -88.02 | 52.12 | 38.81 | 59.85 | -3.44 | Upgrade
|
| Free Cash Flow Per Share | - | -11.70 | 6.92 | 5.16 | 7.95 | -0.46 | Upgrade
|
| Gross Margin | 28.13% | 27.38% | 22.28% | 18.87% | 17.64% | 20.29% | Upgrade
|
| Operating Margin | 8.97% | 9.15% | 7.62% | 6.21% | 6.20% | 7.13% | Upgrade
|
| Profit Margin | 3.74% | 3.84% | 3.53% | 2.37% | 3.25% | 3.36% | Upgrade
|
| Free Cash Flow Margin | - | -7.71% | 3.31% | 2.43% | 3.71% | -0.28% | Upgrade
|
| EBITDA | 112.98 | 128.9 | 144.26 | 118.58 | 116.9 | 99.83 | Upgrade
|
| EBITDA Margin | 11.45% | 11.30% | 9.18% | 7.43% | 7.25% | 8.13% | Upgrade
|
| D&A For EBITDA | 24.48 | 24.48 | 24.48 | 19.44 | 16.96 | 12.23 | Upgrade
|
| EBIT | 88.5 | 104.42 | 119.78 | 99.15 | 99.94 | 87.6 | Upgrade
|
| EBIT Margin | 8.97% | 9.15% | 7.62% | 6.21% | 6.20% | 7.13% | Upgrade
|
| Effective Tax Rate | 24.44% | 22.14% | 19.83% | 23.28% | 25.29% | 27.66% | Upgrade
|
| Revenue as Reported | 989.17 | 1,143 | 1,573 | 1,603 | 1,614 | 1,231 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.